Aptevo Therapeutics Files 8-K for Material Agreement

TL;DR

APVO filed an 8-K on 9/18 for a material agreement signed 9/16.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on September 18, 2024, reporting a material definitive agreement entered into on September 16, 2024. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Seattle, Washington.

Why It Matters

This 8-K filing indicates a significant new agreement for Aptevo Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• September 16, 2024 (date) — Date of earliest event reported
• September 18, 2024 (date) — Date of Report
• 206-838-0500 (phone_number) — Registrant's Telephone Number
• 2401 4th Avenue Suite 1050 (address) — Principal Executive Offices
• Seattle, Washington 98121 (address) — Principal Executive Offices Location

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
• $0.33 — n Stock at a combined offering price of $0.33 per share and accompanying Common Warra
• $0.3299 — n Stock at a combined offering price of $0.3299 per Pre-funded Warrant and accompanying
• $0.0001 — nd accompanying Common Warrant less the $0.0001 per share exercise price of each such P
• $0.515 — Common Stock and have exercise price of $0.515 per share, (ii) April 15, 2024 to purch
• $2.5 million — received net proceeds of approximately $2.5 million from the Offering, after deducting the

Filing Documents

• apvo-20240916.htm (8-K) — 60KB
• apvo-ex4_1.htm (EX-4.1) — 197KB
• apvo-ex4_2.htm (EX-4.2) — 156KB
• apvo-ex10_1.htm (EX-10.1) — 161KB
• apvo-ex10_2.htm (EX-10.2) — 321KB
• apvo-ex10_3.htm (EX-10.3) — 195KB
• apvo-ex10_4.htm (EX-10.4) — 207KB
• apvo-ex10_5.htm (EX-10.5) — 194KB
• apvo-ex10_6.htm (EX-10.6) — 210KB
• apvo-ex10_7.htm (EX-10.7) — 185KB
• apvo-ex10_8.htm (EX-10.8) — 181KB
• apvo-ex99_1.htm (EX-99.1) — 16KB
• apvo-ex99_2.htm (EX-99.2) — 16KB
• img237228349_0.jpg (GRAPHIC) — 4KB
• img238151870_0.jpg (GRAPHIC) — 4KB
• 0000950170-24-107776.txt ( ) — 2568KB
• apvo-20240916.xsd (EX-101.SCH) — 25KB
• apvo-20240916_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information regarding the Purchase Agreement (as defined below) set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

01 Other Events

Item 8.01 Other Events. On September 16, 2024, Aptevo Therapeutics Inc. (the "Company") announced that it has entered into a securities purchase agreement (the "Purchase Agreement") with certain healthcare-focused institutional investors in connection with a registered direct offering (the "Offering") priced at-the-market under Nasdaq Stock Market rules, to purchase: (i) 4,020,000 shares of its common stock, par value $0.001 per share ("Common Stock") and accompanying common warrants ("Common Warrants") to purchase up to 8,040,000 shares of Common Stock at a combined offering price of $0.33 per share and accompanying Common Warrants and (ii) pre-funded warrants ("Pre-funded Warrants") to purchase 5,070,910 shares of Common Stock and accompanying Common Warrants to purchase up to 10,141,820 shares of Common Stock at a combined offering price of $0.3299 per Pre-funded Warrant and accompanying Common Warrants, which is equal to the offering price per share of Common Stock and accompanying Common Warrant less the $0.0001 per share exercise price of each such Pre-funded Warrant. Each share of Common Stock or Pre-Funded Warrant in lieu thereof was offered together with two Common Warrants, each to purchase one share of Common Stock. The Common Warrants have an exercise price of $0.33 per share of Common Stock. The Common Warrants are exercisable upon stockholder approval and will expire five years from the date of stockholder approval. The exercise price of the Common Warrants is subject to adjustment for stock splits, share dividends, share combinations and similar capital transactions and in the event of an issuance of common stock or common stock equivalent, an option to purchase common stock or common stock equivalent, change in price of common stock or common stock equivalent or other such event as further described in the Common Warrants.

01 Other Events

Item 8.01 Other Events. The Company issued press releases announcing the Offering and the closing of the Offering on September 16, 2024 and September 18, 2024, respectively. Copies of these press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 4.1 Common Warrant, dated September 18, 2024. 4.2 Pre-funded Warrant, dated September 18, 2024. 10.1 Placement Agency Agreement, dated September 16, 2024, between the Company and Roth Capital Partners. 10.2 Securities Purchase Agreement, dated September 16, 2024, between the Company and the purchasers party thereto. 10.3 Form of Amended Series A-1 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. 10.4 Form of Amended Series A-2 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. 10.5 Form of Amended Series B-1 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. 10.6 Form of Amended Series B-2 Common Warrant, dated September 18, 2024 (originally entered into on November 9, 2023), between the Company and certain warrant holders. 10.7 Form of Amended Warrant, dated September 18, 2024 (originally entered into on April 15, 2024), between the Company and certain warrant holders. 10.8 Form of Amended Warrant, dated September 18, 2024 (originally entered into on July 1, 2024), between the Company and certain warrant holders. 99.1 Press Release of Aptevo Therapeutics Inc., dated September 16, 2024. 99.2 Press Release of Aptevo Therapeutics Inc., dated September 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: September 18, 2024 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR